Getting bad news from the Food and Drug Administration is never a good thing. But neglecting to inform the market immediately just makes the problem worse.. Danish drug maker Novo Nordisk on Monday said it would pay a 500,000 Danish kroner ($89,854) fine imposed by Denmark’s public prosecutor for failing to immediately tell investors about a rejection letter from the FDA concerning two of the company’s insulin products.